MedTrace Logo

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

NCT04398147 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 696

Last updated 2020-07-02

No results posted yet for this study

Summary

This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to \<55 and 65 to \<85 years of age，with the randomized, observer-blind, dose-escalation design

Conditions

Interventions

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular administration

BIOLOGICAL

Placebo

Intramuscular administration

Sponsors & Collaborators

  • Beijing Institute of Biotechnology

    collaborator OTHER

  • Canadian Center for Vaccinology

    collaborator OTHER

  • CanSino Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Scott A Halperin, MD · Canadian Center for Vaccinology

  • Joanne M Langley, MD · Canadian Center for Vaccinology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-12-20
Completion
2021-12-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398147 on ClinicalTrials.gov